M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update.
Kavita Mishra,Sarah Squire,Kathleen R. Lamborn,Anuradha Banerjee,Nalin Gupta,William M. Wara,Michael D. Prados,Mitchel S. Berger,Daphne A. Haas-Kogan +8 more
TL;DR: Long-term results for children with low-grade hypothalamic/chiasmatic gliomas treated on a phase II chemotherapy protocol show age at diagnosis was significantly associated with relapse and survival, and no PFS or OS benefit was seen with STR versus biopsy/no sampling.
Journal ArticleDOI
It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology
Patrick Y. Wen,David Schiff,Timothy F. Cloughesy,David A. Reardon,Tracy T. Batchelor,Bruce A. Chabner,Keith T. Flaherty,John de Groot,Mark R. Gilbert,Evanthia Galanis,Susan M. Chang,Gary K. Schwartz,David M. Peereboom,Minesh P. Mehta,W. K. Alfred Yung,Stuart A. Grossman,Michael D. Prados,Lisa M. DeAngelis +17 more
TL;DR: It is suggested that the reasons for excluding patients with primary brain tumors from phase I studies are largely obsolete and it is time to reconsider this practice and include patients with brain tumors in phase I trials in oncology.
Journal ArticleDOI
Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
Sarah J. Nelson,Yan Li,Janine M. Lupo,Marram P. Olson,Jason C. Crane,Annette M. Molinaro,Ritu Roy,Jennifer Clarke,Nicholas Butowski,Michael D. Prados,Soonmee Cha,Susan M. Chang +11 more
TL;DR: Integrating metabolic parameters into the assessment of patients with newly diagnosed GBM receiving therapies that include anti-angiogenic agents may be helpful for tracking changes in tumor burden, resolving ambiguities in anatomic images caused by non-specific treatment effects and for predicting outcome.
Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience
Brandon S. Imber,Steve Braunstein,Fred Y. Wu,Nima Nabavizadeh,Nicholas Boehling,Vivian Weinberg,Tarik Tihan,Michael J. Barnes,Sabine Mueller,Nicholas Butowski,Jennifer Clarke,Susan M. Chang,Michael M. McDermott,Michael D. Prados,Mitchel S. Berger,Daphne A. Haas-Kogan +15 more
TL;DR: In this paper, the authors evaluated the effects of tumor atypia, size, resection extent, and adjuvant radiotherapy on progression-free survival (PFS) of 28 patients with atypical neurocytomas.
Journal ArticleDOI
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.
Fred H. Hochberg,Michael D. Prados,Christy A. Russell,David E. Weissman,Richard G. Evans,P. Cook,Gary V. Burton,Peter D. Eisenberg,Raul F. Valenzuela,Lev Verkh +9 more
TL;DR: Fluosol may enhance the effectiveness of BCNU for the treatment of recurrent malignant gliomas and future studies will be performed using fluosol at the dose of400 ml/m2.